

## Supporting Information

### Enantioselective Formation of Tertiary and Quaternary Allylic C-N Bonds via Allylation of Tetrazoles

Kun Xu, Wilfried Raimondi, Timm Bury and Bernhard Breit\*

*Institut für Organische Chemie, Albert-Ludwigs-Universität Freiburg, Albertstrasse 21, 79104 Freiburg, Germany*

---

#### Table of Contents

General and Materials	S2
Optimization	S3
General Procedure for Rhodium Catalyzed Coupling of Tetrazoles with Allenes	S4
Syntheses and Characterization of $N^2$ -allylated Tetrazoles	S4
Gram Scale Prenylation of Phenyltetrazole	S5
Derivatization of $N^2$ -allylated Tetrazoles	S6
Deuterium Labeling Experiment and Proposed Mechanism	S7
References	S8
NMR spectra and HPLC data	S9

## General

**FCC** (Flash Column Chromatography) was accomplished using MACHEREY-NAGEL silica gel 60<sup>®</sup> (230-400 mesh). **TLC** (Thin Layer Chromatography) was performed on aluminum plates pre-coated with silica gel (MERCK, 60F<sub>254</sub>), which were visualized by UV fluorescence ( $\lambda_{\text{max}} = 254$  nm) and/or by staining with 1% w/v KMnO<sub>4</sub> in 0.5 M aqueous K<sub>2</sub>CO<sub>3</sub>. **NMR** (Nuclear Magnetic Resonance) spectra were acquired on a BRUKER Avance 400 spectrometer (400 MHz and 100.6 MHz for <sup>1</sup>H and <sup>13</sup>C respectively) and/or on a VARIAN Mercury (300 MHz and 75.5 MHz for <sup>1</sup>H and <sup>13</sup>C respectively). All <sup>1</sup>H NMR spectra are reported in parts per million (ppm) downfield of TMS and were measured relative to the signals at 7.26 ppm (CHCl<sub>3</sub>). All <sup>13</sup>C NMR spectra were reported in ppm relative to residual CHCl<sub>3</sub> (77.16 ppm) and were obtained with <sup>1</sup>H-decoupling. Data for <sup>1</sup>H NMR are described as following: chemical shift ( $\delta$  in ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; sx, sextet; m, multiplet; app, apparent; br, broad signal), coupling constant (Hz), integration. Data for <sup>13</sup>C NMR spectra are described in terms of chemical shift ( $\delta$  in ppm). **HRMS** (High resolution mass spectra) were obtained on a FINNIGAN MAT 8200 instrument (CI/NH<sub>3</sub>: 110 eV; EI: 70 eV). **MS-CI** (Chemical ionization mass spectrometry) was performed on a TSQ 700 or MAT 95XL mass spectrometer from Thermo Fisher Scientific Inc. at an ionization energy of 110 eV and a source temperature of 200 °C. Ammonia or isobutene were used as reactant gases. Ammonia or isobutene were used as reactant gases. **Chiral HPLC** was performed on a MERCK HITACHI HPLC apparatus (pump: L-7100, UV detector: D-7400, oven: L-7360; columns: AD-H, AD-3, AS, OD-3, OD-H and OJ-H 15-25 cm 4.6 cm, DAICEL). The **Optical Rotation** of chiral compounds was determined on a PERKIN-ELMER PE 241 apparatus and transformed for a given temperature according to the following formula:

$$[\alpha]_D^T = \frac{\alpha \cdot 100}{c \cdot d}$$


$\alpha$ : measured value for optical rotation;  $c$ : concentration in g/100 ml;  $d$ : length of the cuvette in dm;  $T$ : temperature in °C.

## Materials

**Solvents:** 1,2-Dichloroethane (DCE) were freshly distilled over CaH<sub>2</sub> and degassed by three Freeze-Pump-Thaw cycles prior to use. Tetrahydrofuran (THF) was purchased in HPLC grade quality and was purified by continuous distillation over potassium under argon. Solvents employed for work-up and column chromatography were purchased in technical grade quality and distilled by rotary evaporator before use. **Substrates:** Tetrazoles were purchased from Sigma-Aldrich, ABCR, Alfa Aesar and used without further purification, 5-(naphthalen-2-yl)-1*H*-tetrazole<sup>[1]</sup> was prepared according to the literature. Cyclohexylallene, propa-1,2-dien-1-ylcyclopentane, octa-1,2-diene, hexa-4,5-dien-1-ylbenzene, methyl hepta-5,6-dienoate, 2-(hexa-4,5-dien-1-yl)isoindoline-1,3-dione, (3-methylpenta-3,4-dien-1-yl)benzene, *tert*-butyldimethyl((2-methylbuta-2,3-dien-1-yl)oxy)silane, buta-2,3-dien-2-yltrimethylsilane and (2-methylbuta-2,3-dien-1-yl)benzene were synthesized according to literature procedures.<sup>[2]</sup> 5-phenyl-1*D*-tetrazole was prepared according to the literature.<sup>[3]</sup> **Ligands and catalysts:** [Rh(COD)Cl]<sub>2</sub> and ligands were purchased from Sigma-Aldrich, ABCR, Alfa Aesar and used without further purification.

## Optimization


Optimization of Rhodium Catalyzed Coupling of 5-Phenyl-1*H*-tetrazole with Cyclohexylallene



Entry	Ligand	x	y	z	Temp	yield <sup>a</sup>	ee <sup>b</sup>
1	DPEphos	1.2	1.0	3.0	80	98	-
2	(R)-Segphos	1.2	1.0	3.0	80	89	33
3	(S)-(-)-MeO-BIPHEP	1.2	1.0	3.0	80	84	48
4	(R)-DIFLUORPHOS	1.2	1.0	3.0	80	99	10
5	(S)-SYNPHOS	1.2	1.0	3.0	80	91	43
6	(R)-C <sub>3</sub> -TunePhos	1.2	1.0	3.0	80	93	51
7	Josiphos SL-J001-1	1.2	1.0	3.0	80	Quant.	0
8	Josiphos SL-J002-1	1.2	1.0	3.0	80	49	41
9	Josiphos SL-J004-1	1.2	1.0	3.0	80	83	14
10	<b>L5</b>	1.2	1.0	3.0	60	n.r <sup>c</sup>	-
11	-	1.2	1.0	3.0	60	n.r <sup>d</sup>	-

<sup>a</sup> Isolated yield; <sup>b</sup> Determined by chiral HPLC; <sup>c</sup> Reaction in the absence of [Rh(CODCl)<sub>2</sub>]; <sup>d</sup> Reaction in the absence of Ligand.

## General Procedure for Rhodium Catalyzed Coupling of Tetrazoles with Allenes




The reaction was performed in a 2.0 ml Schlenk tube under argon.  $[\text{Rh}(\text{COD})\text{Cl}]_2$  (2.0 mg, 0.004 mmol, 2.0 mol%), JoSPOphos SL-J688-2 (4.8 mg, 0.01 mmol, 5.0 mol%), tetrazole (0.2 mmol, 1.0 equiv) were dissolved in DCE (1.0 mL), then allene (0.4 mmol, 2.0 equiv.) was added and the tube was sealed. The reaction mixture was stirred at corresponding temperature for 18 hours. After cooling to room temperature, the solvent was removed by rotary evaporation. The crude product was purified by flash column chromatography on silica gel and dried *in vacuo*.

## Syntheses and Characterization of $N^2$ -allylated Tetrazoles

### 1 Enantioselective Formation of Tertiary Allylic C-N Bonds (**1a-I**)


#### 1.1 (S)-2-(1-cyclohexylallyl)-5-phenyl-2*H*-tetrazole (**1a**)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and cyclohexylallene (58  $\mu\text{L}$ , 48.9 mg, 0.4 mmol) at 60  $^\circ\text{C}$ . The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30,  $R_f$  = 0.35) to afford the product as a yellowish oil (43.0 mg, 80%).

**$^1\text{H NMR}$**  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 8.19 - 8.14 (m, 2 H), 7.51 - 7.45 (m, 3 H), 6.23 (ddd,  $J$  = 8.8, 10.4, 17.1 Hz, 1 H), 5.39 - 5.32 (m, 2 H), 5.06 (t,  $J$  = 9.0 Hz, 1 H), 2.19 - 2.07 (m, 1 H), 1.93 - 1.85 (m, 1 H), 1.83 - 1.75 (m, 1 H), 1.74 - 1.62 (m, 2 H), 1.35 - 1.12 (m, 4 H), 1.09 - 0.95 (m, 2 H);  **$^{13}\text{C NMR}$**  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  = 164.9, 133.7, 130.2, 128.9, 127.8, 126.9, 126.5, 120.5, 72.9, 41.9, 29.5, 29.4, 26.1, 25.8, 25.6; **HRMS-APCI** (MeOH, m/z):  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{16}\text{H}_{21}\text{N}_4$ , 269.17662; found, 269.17660. **HPLC** (CHIRALCEL® L-C2, *n*-heptane /  $i\text{PrOH}$  = 100:1, 0.5 mL/min)  $t_R$  = 7.95 min (minor),  $t_R$  = 9.61 min (major), 87% *ee* (**S**);  $[\alpha]_D^{25} = +81.9$  ( $c$  = 0.675,  $\text{CH}_2\text{Cl}_2$ ).


#### 1.2 (S)-2-(1-cyclohexylallyl)-5-(p-tolyl)-2*H*-tetrazole (**1b**)



The reaction was performed with 5-(p-tolyl)-1*H*-tetrazole (32.0 mg, 0.2 mmol) and cyclohexylallene (58  $\mu\text{L}$ , 48.9 mg, 0.4 mmol) at 60  $^\circ\text{C}$ . The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30,  $R_f$  = 0.29) to afford the product as a yellowish solid (46.3 mg, 82%).

**m.p.:** 48 – 49 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.07 - 8.02 (m, 2 H), 7.32 - 7.27 (m, 2 H), 6.23 (ddd, *J* = 8.9, 10.3, 17.0 Hz, 1 H), 5.38 - 5.31 (m, 2 H), 5.04 (t, *J* = 9.0 Hz, 1 H), 2.41 (s, 3 H), 2.19 - 2.07 (m, 1 H), 1.93 - 1.84 (m, 1 H), 1.83 - 1.75 (m, 1 H), 1.73 - 1.62 (m, 2 H), 1.35 - 1.12 (m, 4 H), 1.08 - 0.94 (m, 2 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 165.0, 140.4, 133.8, 129.6, 126.9, 125.0, 120.4, 72.8, 41.9, 29.5, 29.4, 26.1, 25.8, 25.6, 21.6; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>N<sub>4</sub>, 283.19227; found, 283.19170. **HPLC** (CHIRALCEL® AD-3, *n*-heptane /<sup>i</sup>PrOH = 100:1, 1 mL/min) t<sub>R</sub> = 21.51 min (minor), t<sub>R</sub> = 23.26 min (major), 91% *ee* (*S*); [α]<sub>D</sub><sup>25</sup> = + 81.0 (c = 0.815, CH<sub>2</sub>Cl<sub>2</sub>).


### 1.3 (*S*)-2-(1-cyclohexylallyl)-5-(4-fluorophenyl)-2*H*-tetrazole (**1c**)



The reaction was performed with 5-(4-fluorophenyl)-1*H*-tetrazole (32.8 mg, 0.2 mmol) and cyclohexylallene (58 μL, 48.9 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30, R<sub>f</sub> = 0.31) to afford the product as a yellowish oil (43.0 mg, 75%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.19 - 8.12 (m, 2 H), 7.21 - 7.13 (m, 2 H), 6.22 (ddd, *J* = 8.9, 10.3, 17.1 Hz, 1 H), 5.39 - 5.32 (m, 2 H), 5.05 (t, *J* = 9.0 Hz, 1 H), 2.18 - 2.07 (m, 1 H), 1.93 - 1.85 (m, 1 H), 1.83 - 1.75 (m, 1 H), 1.74 - 1.62 (m, 2 H), 1.35 - 1.09 (m, 4 H), 1.09 - 0.94 (m, 2 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.2, 164.0 (d, *J* = 250.3 Hz), 133.6, 129.0 (d, *J* = 8.5 Hz), 124.0, 124.0, 120.6, 116.0 (d, *J* = 22.9 Hz), 73.0, 41.9, 29.5, 29.4, 26.1, 25.8, 25.6; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>20</sub>N<sub>4</sub>F, 287.16720; found, 287.16680. **HPLC** (CHIRALCEL® L-C4, *n*-heptane /<sup>i</sup>PrOH = 600:1, 1 mL/min) t<sub>R</sub> = 14.92 min (major), t<sub>R</sub> = 23.15 min (minor), 87% *ee* (*S*); [α]<sub>D</sub><sup>25</sup> = + 74.3 (c = 0.580, CH<sub>2</sub>Cl<sub>2</sub>).

### 1.4 (*S*)-5-(4-chlorophenyl)-2-(1-cyclohexylallyl)-2*H*-tetrazole (**1d**)



The reaction was performed with 5-(4-chlorophenyl)-1*H*-tetrazole (36.1 mg, 0.2 mmol) and cyclohexylallene (58 μL, 48.9 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30, R<sub>f</sub> = 0.34) to afford the product as a yellowish oil (51.5 mg, 85%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.12 - 8.07 (m, 2 H), 7.48 - 7.43 (m, 2 H), 6.21 (ddd, *J* = 8.8, 10.3, 17.0 Hz, 1 H), 5.39 - 5.31 (m, 2 H), 5.05 (t, *J* = 9.0 Hz, 1 H), 2.18 - 2.06 (m, 1 H), 1.92 - 1.84 (m, 1 H), 1.83 - 1.74 (m, 1 H), 1.73 - 1.60 (m, 2 H), 1.33 - 1.12 (m, 4 H), 1.08 - 0.94 (m, 2 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.1, 136.3, 133.6, 129.2, 128.2, 126.3, 120.7, 73.0, 41.9, 29.5, 29.4, 26.1, 25.7, 25.6; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>20</sub>N<sub>4</sub><sup>35</sup>Cl, 303.13765; found, 303.13710. **HPLC** (CHIRALCEL® L-C4, *n*-heptane /<sup>i</sup>PrOH = 600:1, 1 mL/min) t<sub>R</sub> = 14.77 min (major), t<sub>R</sub> = 21.39 min (minor), 87% *ee* (*S*); [α]<sub>D</sub><sup>25</sup> = + 78.2 (c = 0.680, CH<sub>2</sub>Cl<sub>2</sub>).


### **1.5 (S)-5-(4-bromophenyl)-2-(1-cyclohexylallyl)-2*H*-tetrazole (**1e**)**



The reaction was performed with 5-(4-bromophenyl)-1*H*-tetrazole (45.0 mg, 0.2 mmol) and cyclohexylallene (58  $\mu$ L, 48.9 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30,  $R_f$  = 0.34) to afford the product as a yellowish solid (55.5 mg, 80%).

**m.p.:** 52 – 53 °C.  **$^1\text{H NMR}$**  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 8.05 - 8.01 (m, 2 H), 7.64 - 7.59 (m, 2 H), 6.21 (ddd,  $J$  = 8.9, 10.3, 17.1 Hz, 1 H), 5.38 - 5.31 (m, 2 H), 5.04 (t,  $J$  = 9.0 Hz, 1 H), 2.17 - 2.06 (m, 1 H), 1.92 - 1.84 (m, 1 H), 1.82 - 1.74 (m, 1 H), 1.74 - 1.61 (m, 2 H), 1.34 - 1.12 (m, 4 H), 1.10 - 0.93 (m, 2 H);  **$^{13}\text{C NMR}$**  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  = 164.1, 133.6, 132.2, 128.5, 126.7, 124.6, 120.7, 73.0, 41.9, 29.5, 29.4, 26.1, 25.7, 25.6; **HRMS-APCI** (MeOH, m/z):  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{16}\text{H}_{20}\text{N}_4^{79}\text{Br}$ , 347.08713; found, 347.08650. **HPLC** (CHIRALCEL® L-C4, *n*-heptane /  $^3\text{PrOH}$  = 1000:1, 1 mL/min)  $t_R$  = 31.88 min (major),  $t_R$  = 47.36 min (minor), 89% *ee* (*S*);  $[\alpha]_D^{25}$  = + 72.2 (c = 0.615,  $\text{CH}_2\text{Cl}_2$ ).

### **1.6 (S)-3-(2-(1-cyclohexylallyl)-2*H*-tetrazol-5-yl)aniline (**1f**)**



The reaction was performed with 3-(1*H*-tetrazol-5-yl)aniline (32.2 mg, 0.2 mmol) and cyclohexylallene (58  $\mu$ L, 48.9 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:3,  $R_f$  = 0.32) to afford the product as a yellowish oil (39.1 mg, 69%).

**$^1\text{H NMR}$**  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.57 - 7.52 (m, 1 H), 7.49 (dd,  $J$  = 1.3, 2.5 Hz, 1 H), 7.30 - 7.22 (m, 1 H), 6.77 (ddd,  $J$  = 1.0, 2.5, 8.0 Hz, 1 H), 6.22 (ddd,  $J$  = 8.8, 10.3, 17.0 Hz, 1 H), 5.37 - 5.30 (m, 2 H), 5.04 (t,  $J$  = 9.0 Hz, 1 H), 3.77 (br. s., 2 H), 2.17 - 2.05 (m, 1 H), 1.92 - 1.83 (m, 1 H), 1.82 - 1.59 (m, 4 H), 1.34 - 0.92 (m, 6 H);  **$^{13}\text{C NMR}$**  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  = 165.0, 146.9, 133.7, 129.9, 128.6, 120.4, 117.2, 116.9, 113.2, 72.8, 41.9, 29.5, 29.4, 26.1, 25.7, 25.6; **HRMS-APCI** (MeOH, m/z):  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{16}\text{H}_{22}\text{N}_4$ , 284.18752; found, 284.18770. **HPLC** (CHIRALCEL® OD-H, *n*-heptane /  $^3\text{PrOH}$  = 80:20, 1 mL/min)  $t_R$  = 12.43 min (minor),  $t_R$  = 14.54 min (major), 80% *ee* (*S*);  $[\alpha]_D^{25}$  = + 63.9 (c = 0.735,  $\text{CH}_2\text{Cl}_2$ ).


### **1.7 (S)-2-(1-cyclohexylallyl)-5-(naphthalen-2-yl)-2*H*-tetrazole (**1g**)**



The reaction was performed with 5-(naphthalen-2-yl)-1*H*-tetrazole (39.2 mg, 0.2 mmol) and cyclohexylallene (58  $\mu$ L, 48.9 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30,  $R_f$  = 0.25) to afford the product as a white solid (45.9 mg, 72%).

**m.p.:** 57 – 59 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.70 (dd, *J* = 0.8, 1.5 Hz, 1 H), 8.25 (dd, *J* = 1.6, 8.6 Hz, 1 H), 7.99 - 7.93 (m, 2 H), 7.90 - 7.84 (m, 1 H), 7.56 - 7.50 (m, 2 H), 6.27 (ddd, *J* = 8.8, 10.5, 16.8 Hz, 1 H), 5.40 - 5.35 (m, 2 H), 5.14 - 5.07 (m, 1 H), 2.24 - 2.11 (m, 1 H), 1.96 - 1.88 (m, 1 H), 1.85 - 1.76 (m, 1 H), 1.74 - 1.61 (m, 2 H), 1.37 - 0.98 (m, 6 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 165.1, 134.3, 133.7, 133.4, 128.8, 128.7, 128.0, 127.1, 126.7, 125.1, 124.1, 120.6, 73.0, 42.0, 29.6, 29.5, 26.2, 25.8, 25.6; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>, 319.19227; found, 319.19220. **HPLC** (CHIRALCEL® OD-3, *n*-heptane / *i*PrOH = 300:1, 0.5 mL/min) t<sub>R</sub> = 23.91 min (major), t<sub>R</sub> = 26.79 min (minor), 86% *ee* (**S**); [α]<sub>D</sub><sup>25</sup> = + 83.3 (c = 0.545, CH<sub>2</sub>Cl<sub>2</sub>).

### 1.8 (*S*)-2-(1-cyclopentylallyl)-5-phenyl-2*H*-tetrazole (**1h**)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and propa-1,2-dien-1-ylcyclopentane (43.3 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30, R<sub>f</sub> = 0.36) to afford the product as a colorless oil (47.3 mg, 93%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.19 - 8.15 (m, 2 H), 7.51 - 7.41 (m, 3 H), 6.21 (ddd, *J* = 8.2, 10.1, 17.3 Hz, 1 H), 5.33 - 5.28 (m, 2 H), 5.14 - 5.08 (m, 1 H), 2.80 - 2.65 (m, 1 H), 1.93 - 1.80 (m, 1 H), 1.73 - 1.45 (m, 5 H), 1.44 - 1.31 (m, 1 H), 1.28 - 1.17 (m, 1 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.9, 134.5, 130.2, 128.9, 127.8, 126.9, 119.6, 72.1, 44.2, 29.9, 29.7, 25.4, 25.1; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>N<sub>4</sub>, 255.16097; found, 255.16100. **HPLC** (CHIRALCEL® AD-3, *n*-heptane / *i*PrOH = 98:2, 1 mL/min) t<sub>R</sub> = 8.60 min (minor), t<sub>R</sub> = 9.37 min (major), 90% *ee* (**S**); [α]<sub>D</sub><sup>25</sup> = + 78.5 (c = 0.480, CH<sub>2</sub>Cl<sub>2</sub>).

### 1.9 (*R*)-2-(oct-1-en-3-yl)-5-phenyl-2*H*-tetrazole (**1i**)




The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and octa-1,2-diene (44.1 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:15, R<sub>f</sub> = 0.40) to afford the product as a yellowish oil (39.0 mg, 76%).


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = <sup>1</sup>H NMR (400MHz ,CHLOROFORM-d) δ = 8.19 - 8.13 (m, 2 H), 7.51 - 7.42 (m, 3 H), 6.16 (ddd, *J* = 7.6, 10.5, 17.1 Hz, 1 H), 5.38 - 5.27 (m, 3 H), 2.29 - 2.17 (m, 1 H), 2.10 - 1.97 (m, 1 H), 1.40 - 1.14 (m, 6 H), 0.88 - 0.83 (m, 3 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = <sup>13</sup>C NMR (101MHz ,CHLOROFORM-d) δ = 165.0, 135.1, 130.3, 128.9, 127.8, 126.9, 119.0, 67.3, 34.6, 31.2, 25.4, 22.4, 14.0; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>21</sub>N<sub>4</sub>, 257.17662; found, 257.17670. **HPLC** (CHIRALCEL® AD-3, *n*-heptane / *i*PrOH = 200:1, 1 mL/min) t<sub>R</sub> = 7.59 min (major), t<sub>R</sub> = 8.13 min (minor), 84% *ee* (**R**); [α]<sub>D</sub><sup>25</sup> = - 57.7 (c = 0.565, CH<sub>2</sub>Cl<sub>2</sub>).

**Determination of absolute configuration:** Absolute configuration was determined by comparing the specific rotation the derivatized<sup>[4]</sup> product with literature.<sup>[5]</sup> Hydroboration of **1i** followed by oxidation with H<sub>2</sub>O<sub>2</sub> under

basic condition gave the corresponding aniline derivatives **1ia**. (*R*)-3-(5-phenyl-2*H*-tetrazol-2-yl)octan-1-ol (**1ia**):  $[\alpha]_D^{20} = + 2.86$  ( $c = 0.595$ ,  $\text{CH}_2\text{Cl}_2$ ). Literature value of (*S*)-3-(5-phenyl-2*H*-tetrazol-2-yl)octan-1-ol: 85% *ee*,  $[\alpha]_D^{20} = - 2.4$  ( $c = 1.0$ ,  $\text{CH}_2\text{Cl}_2$ ). The absolute configurations for other allylation products were assigned by analogy.



### 1.10 (*R*)-5-phenyl-2-(6-phenylhex-1-en-3-yl)-2*H*-tetrazole (**1j**)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and hexa-4,5-dien-1-ylbenzene (63.3 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:15,  $R_f = 0.32$ ) to afford the product as a yellowish oil (45.7 mg, 75%).

**<sup>1</sup>H NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta = 8.18 - 8.14$  (m, 2 H), 7.52 - 7.46 (m, 3 H), 7.30 - 7.24 (m, 2 H), 7.21 - 7.12 (m, 3 H), 6.15 (ddd,  $J = 7.6, 10.4, 17.1$  Hz, 1 H), 5.41 - 5.34 (m, 1 H), 5.34 - 5.27 (m, 2 H), 2.66 (t,  $J = 7.5$  Hz, 2 H), 2.35 - 2.23 (m, 1 H), 2.14 - 2.04 (m, 1 H), 1.78 - 1.48 (m, 2 H); **<sup>13</sup>C NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta = 165.1, 141.4, 134.9, 130.3, 128.9, 128.5, 128.4, 127.7, 127.0, 126.1, 119.3, 67.1, 35.2, 34.0, 27.5; **HRMS-APCI** (MeOH, m/z):  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{19}\text{H}_{21}\text{N}_4$ , 305.17662; found, 305.17660. **HPLC** (CHIRALCEL® L-C2, *n*-heptane / *i*PrOH = 200:1, 0.5 mL/min)  $t_R = 27.57$  min (major),  $t_R = 51.47$  min (minor), 90% *ee* (**R**);  $[\alpha]_D^{25} = + 37.4$  ( $c = 0.700$ ,  $\text{CH}_2\text{Cl}_2$ ).$

### 1.11 (*R*)-methyl 5-(5-phenyl-2*H*-tetrazol-2-yl)hept-6-enoate (**1k**)




The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and methyl hepta-5,6-dienoate (56.1 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:15,  $R_f = 0.28$ ) to afford the product as a colorless oil (39.5 mg, 69%).

**<sup>1</sup>H NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta = 8.17 - 8.12$  (m, 2 H), 7.49 - 7.40 (m, 3 H), 6.14 (ddd,  $J = 7.5, 10.5, 17.0$  Hz, 1 H), 5.40 - 5.29 (m, 3 H), 3.64 (s, 3 H), 2.34 (t,  $J = 7.3$  Hz, 2 H), 2.32 - 2.21 (m, 1 H), 2.16 - 2.05 (m, 1 H), 1.78 - 1.63 (m, 1 H), 1.59 - 1.46 (m, 1 H); **<sup>13</sup>C NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta = 173.2, 165.1, 134.6, 130.3, 128.9, 127.6, 126.9, 119.4, 66.8, 51.6, 33.8, 33.2, 21.2; **HRMS-APCI** (MeOH, m/z):  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{15}\text{H}_{19}\text{O}_2\text{N}_4$ , 287.15080; found, 287.15080.$

**HPLC** (CHIRALCEL® AD-3, *n*-heptane / *i*PrOH = 200:1, 1 mL/min)  $t_R$  = 55.98 min (minor),  $t_R$  = 60.81 min (major), 84% *ee* (*S*);  $[\alpha]_D^{25}$  = - 51.3 (c = 0.435, CH<sub>2</sub>Cl<sub>2</sub>).

### 1.12 (*R*)-2-(4-(5-phenyl-2*H*-tetrazol-2-yl)hex-5-en-1-yl)isoindoline-1,3-dione (**1l**)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and 2-(hexa-4,5-dien-1-yl)isoindoline-1,3-dione (90.9 mg, 0.4 mmol) at 60 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:3,  $R_f$  = 0.35) to afford the product as a white solid (53.8 mg, 72%).

**m.p.**: 113 – 114 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.14 - 8.11 (m, 2 H), 7.85 - 7.81 (m, 2 H), 7.73 - 7.69 (m, 2 H), 7.49 - 7.44 (m, 3 H), 6.20 - 6.09 (m, 1 H), 5.48 - 5.41 (m, 1 H), 5.37 - 5.31 (m, 2 H), 3.82 - 3.67 (m, 2 H), 2.38 - 2.24 (m, 1 H), 2.10 (tdd, *J* = 6.1, 10.5, 14.0 Hz, 1 H), 1.82 - 1.57 (m, 2 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 168.4, 165.1, 134.5, 134.1, 132.1, 130.3, 128.9, 127.6, 127.0, 123.4, 119.7, 66.6, 37.1, 31.7, 25.0; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>O<sub>2</sub>N<sub>5</sub>, 374.16170; found, 374.16170. **HPLC** (CHIRALCEL® L-C2, *n*-heptane / *i*PrOH = 50:50, 0.5 mL/min)  $t_R$  = 14.12 min (minor),  $t_R$  = 26.35 min (major), 86% *ee* (*S*);  $[\alpha]_D^{25}$  = + 33.9 (c = 0.585, CH<sub>2</sub>Cl<sub>2</sub>).

## 2 Enantioselective Formation of Quaternary Allylic C-N Bonds (**2a-f**)


### 2.1 (*S*)-2-(2-(adamantan-1-yl)but-3-en-2-yl)-5-phenyl-2*H*-tetrazole (**2a**)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and 1-(penta-3,4-dien-2-yl)adamantane (80.9 mg, 0.4 mmol) at 100 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:15,  $R_f$  = 0.43) to afford the product as a white solid (68.2 mg, 99%).

**m.p.**: 116 – 117 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = <sup>1</sup>H NMR (400MHz ,CHLOROFORM-d) d = 8.23 - 8.15 (m, 2 H), 7.53 - 7.41 (m, 3 H), 6.94 (dd, *J* = 11.1, 17.6 Hz, 1 H), 5.40 (dd, *J* = 0.8, 11.1 Hz, 1 H), 5.25 (dd, *J* = 0.8, 17.6 Hz, 1 H), 1.97 (td, *J* = 3.3, 6.5 Hz, 3 H), 1.91 (s, 3 H), 1.71 - 1.60 (m, 6 H), 1.58 - 1.48 (m, 6 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 163.3, 137.1, 130.0, 128.8, 128.1, 126.9, 116.4, 77.3, 75.7, 40.3, 36.9, 36.7, 28.7, 18.0; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>27</sub>N<sub>4</sub>, 335.22357; found, 335.22360. **HPLC** (CHIRALCEL® OD-3, *n*-heptane / *i*PrOH = 98:2, 1 mL/min)  $t_R$  = 2.98 min (major),  $t_R$  = 3.41 min (minor), 74% *ee* (*S*);  $[\alpha]_D^{25}$  = + 49.6 (c = 0.635, CH<sub>2</sub>Cl<sub>2</sub>).


### 2.2 (*R*)-2-((tert-butyldimethylsilyl)oxy)-2-methylbut-3-en-2-yl)-5-phenyl-2*H*-tetrazole (**2b**)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and *tert*-butyldimethyl((2-methylpenta-3,4-dien-1-yl)oxy)silane (85.0 mg, 0.4 mmol) at 100 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:15, R<sub>f</sub> = 0.47) to afford the product as a colorless oil (44.8 mg, 65%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.18 - 8.14 (m, 2 H), 7.50 - 7.42 (m, 3 H), 6.32 (dd, J = 10.9, 17.6 Hz, 1 H), 5.32 (d, J = 10.9 Hz, 1 H), 5.17 (d, J = 17.4 Hz, 1 H), 4.24 (d, J = 10.1 Hz, 1 H), 4.00 (d, J = 10.1 Hz, 1 H), 1.95 (s, 3 H), 0.77 (s, 9 H), -0.01 (s, 3 H), -0.06 (s, 3 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.5, 137.7, 130.1, 128.9, 127.9, 127.0, 116.7, 70.7, 69.0, 25.7, 21.0, 18.1, -5.5, -5.6; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>29</sub>ON<sub>4</sub>Si, 345.21107; found, 345.21120. **HPLC** (CHIRALCEL® L-C2, *n*-heptane / iPrOH = 200:1, 0.5 mL/min) t<sub>R</sub> = 8.19 min (minor), t<sub>R</sub> = 9.62 min (major), 79% *ee* (**R**); [α]<sub>D</sub><sup>25</sup> = -11.2 (c = 0.525, CH<sub>2</sub>Cl<sub>2</sub>).

### 2.3 (S)-5-phenyl-2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazole (2c)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and buta-2,3-dien-2-yltrimethylsilane (50.5 mg, 0.4 mmol) at 100 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:15, R<sub>f</sub> = 0.43) to afford the product as a colorless oil (46.1 mg, 85%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.19 - 8.12 (m, 2 H), 7.52 - 7.41 (m, 3 H), 6.34 (dd, J = 10.9, 17.4 Hz, 1 H), 5.20 (dd, J = 0.6, 10.9 Hz, 1 H), 4.91 (dd, J = 0.6, 17.3 Hz, 1 H), 1.87 (s, 3 H), 0.19 (s, 9 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.2, 138.8, 130.1, 128.9, 128.0, 126.9, 113.2, 77.3, 63.3, 20.2, -3.2; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>21</sub>N<sub>4</sub>Si, 273.15355; found, 273.15360. **HPLC** (CHIRALCEL® OD-3, *n*-heptane / iPrOH = 300:1, 0.5 mL/min) t<sub>R</sub> = 8.87 min (major), t<sub>R</sub> = 10.07 min (minor), 94% *ee* (**S**); [α]<sub>D</sub><sup>25</sup> = +36.6 (c = 0.550, CH<sub>2</sub>Cl<sub>2</sub>).

### 2.4 (S)-5-(p-tolyl)-2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazole (2d)




The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and buta-2,3-dien-2-yltrimethylsilane (50.5 mg, 0.4 mmol) at 100 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:40, R<sub>f</sub> = 0.27) to afford the product as a colorless oil (49.9 mg, 87%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.07 - 8.02 (m, 2 H), 7.31 - 7.26 (m, 2 H), 6.33 (dd, J = 10.9, 17.3 Hz, 1 H), 5.20 (dd, J = 0.5, 11.0 Hz, 1 H), 4.91 (dd, J = 0.6, 17.4 Hz, 1 H), 2.41 (s, 3 H), 1.87 (s, 3 H), 0.19 (s, 9 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = <sup>13</sup>C NMR (101MHz ,CHLOROFORM-d) δ = 164.3, 140.2, 138.9, 129.6, 126.8, 125.2, 113.2, 63.2, 21.6, 20.2, -3.1; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>4</sub>Si, 287.16920; found,

287.1688. **HPLC** (CHIRALCEL® L-C1, *n*-heptane / *i*PrOH = 300:1, 0.5 mL/min)  $t_R$  = 9.67 min (major),  $t_R$  = 11.59 min (minor), 96% *ee* (*S*);  $[\alpha]_D^{25} = +40.0$  (c = 0.520, CH<sub>2</sub>Cl<sub>3</sub>).

### 2.5 (*S*)-5-(4-bromophenyl)-2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazole (2e)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and buta-2,3-dien-2-yltrimethylsilane (50.5 mg, 0.4 mmol) at 100 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:40,  $R_f$  = 0.32) to afford the product as a white solid (63.3 mg, 90%).

**m.p.**: 60 – 61 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  = 8.05 - 8.01 (m, 2 H), 7.63 - 7.59 (m, 2 H), 6.33 (dd, *J* = 10.9, 17.4 Hz, 1 H), 5.21 (dd, *J* = 0.5, 10.9 Hz, 1 H), 4.92 (dd, *J* = 0.5, 17.3 Hz, 1 H), 1.87 (s, 3 H), 0.19 (s, 9 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>)  $\delta$  = 163.5, 138.7, 132.2, 128.4, 127.0, 124.5, 113.4, 63.5, 20.2, -3.2; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>20</sub>N<sub>4</sub><sup>79</sup>BrSi, 351.06406; found, 351.06380; calcd for C<sub>14</sub>H<sub>20</sub>N<sub>4</sub><sup>81</sup>BrSi, 353.06201; found, 353.06170. **HPLC** (CHIRALCEL® 2\*L-A2, *n*-heptane / EtOH = 98:2, 0.5 mL/min)  $t_R$  = 14.37 min (major),  $t_R$  = 15.54 min (minor), 95% *ee* (*S*);  $[\alpha]_D^{25} = +39.8$  (c = 0.530, CH<sub>2</sub>Cl<sub>2</sub>).


### 2.6 (*S*)-3-(2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazol-5-yl)aniline (2f)



The reaction was performed with 5-phenyl-1*H*-tetrazole (29.2 mg, 0.2 mmol) and buta-2,3-dien-2-yltrimethylsilane (50.5 mg, 0.4 mmol) at 100 °C. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:5,  $R_f$  = 0.17) to afford the product as a yellowish oil (42.0 mg, 73%).

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.55 (ddd, *J* = 1.0, 1.5, 7.7 Hz, 1 H), 7.49 (qd, *J* = 0.7, 2.4 Hz, 1 H), 7.28 - 7.23 (m, 1 H), 6.76 (ddd, *J* = 1.0, 2.5, 8.0 Hz, 1 H), 6.33 (dd, *J* = 10.9, 17.4 Hz, 1 H), 5.20 (dd, *J* = 0.5, 10.9 Hz, 1 H), 4.90 (dd, *J* = 0.6, 17.4 Hz, 1 H), 1.86 (s, 3 H), 0.19 (s, 9 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>)  $\delta$  = 164.3, 146.9, 138.8, 129.9, 128.8, 117.2, 116.8, 113.2, 63.3, 20.2, -3.2; **HRMS-APCI** (MeOH, m/z): [M+H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>22</sub>N<sub>5</sub>Si, 228.16445; found, 228.16410. **HPLC** (CHIRALCEL® AD-3, *n*-heptane / EtOH = 95:5, 1 mL/min)  $t_R$  = 11.22 min (minor),  $t_R$  = 12.18 min (major), 97% *ee* (*S*);  $[\alpha]_D^{25} = +35.6$  (c = 0.530, CHCl<sub>3</sub>).

## Gram Scale Prenylation of Phenyltetrazole



The reaction was performed in a 25 ml Schlenk tube under argon.  $[\text{Rh}(\text{COD})\text{Cl}]_2$  (28.6 mg, 0.058 mmol, 1.0 mol%), DPEphos (93.7 mg, 0.174 mmol, 3.0 mol%), phenyltetrazole (847.7 mg, 5.8 mmol, 1.0 equiv) were dissolved in DCE (14.5 mL), then allene (474.1 mg, 6.96 mmol, 1.2 equiv.) was added and the tube was sealed. The reaction mixture was stirred at 80 °C for 18 hours. After cooling to room temperature, the solvent was removed by rotary evaporation. The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:20,  $R_f$  = 0.33) to afford the product as a colorless oil (1.22 g, 98%).

### 2-(2-methylbut-3-en-2-yl)-5-phenyl-2*H*-tetrazole (**3**)




The crude product was purified by flash column chromatography on silica gel (EA / CH = 1:30,  $R_f$  = 0.35) to afford the product as a yellowish oil (43.0 mg, 80%).

**<sup>1</sup>H NMR** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 8.14 - 8.21 (m, 2 H), 7.44 - 7.52 (m, 3 H), 6.29 (dd,  $J=17.3, 10.7$  Hz, 1 H), 5.25 (d,  $J=10.7$  Hz, 1 H), 5.19 (d,  $J=17.3$  Hz, 1 H), 1.93 (s, 6 H); **<sup>13</sup>C NMR** (101 MHz,  $\text{CDCl}_3$ )  $\delta$  = 164.7, 141.1, 130.2, 128.9, 127.9, 127.0, 114.7, 66.8, 27.3; **HRMS-APCI** (MeOH, m/z):  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{12}\text{H}_{15}\text{N}_4$ , 215.12912; found, 215.12924.

## Derivatization of $N^2$ -allylated Tetrazoles

### 1 Synthesis of 3-methyl-3-(5-phenyl-2*H*-tetrazol-2-yl)butan-1-ol (**4a**)



Compound **3** (144.8 mg, 0.6 mmol, 1.00 equiv) was dissolved in dry, degassed THF (3.0 ml, 0.2 M) and cooled to -78 °C. Then 9-BBN (1.5 mmol, 3.00 ml, 2.5 equiv, 0.5 M solution in THF) was added to the reaction vessel. The reaction mixture was stirred for 1 h at -78 °C, then allowed to slowly warm to room temperature and stirred overnight. The resulting solution was cooled to 0 °C, at which time EtOH (1.8 ml, 3 mL/mmol), 3 M NaOH (0.9 ml, 1.5 mL/mmol), and 30% H<sub>2</sub>O<sub>2</sub> (0.9 ml, 1.5 mL/mmol) were added in the specified order. The reaction was allowed to warm to room temperature and was stirred for an additional 6 h. The reaction was diluted with ether, then washed with 1 M NaOH and saturated aqueous NH<sub>4</sub>Cl. The organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated.<sup>[4]</sup> The crude product was purified by flash column silica gel chromatography (CH/EE = 2/1, R<sub>f</sub> = 0.23) to give **4a** (139.2 mg, 99% yield) as a colorless oil.

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.10 - 8.19 (m, 2 H), 7.40 - 7.55 (m, 3 H), 3.67 (t, J=6.7 Hz, 2 H), 2.36 (t, J=6.6 Hz, 2 H), 1.84 (s, 6 H), 1.75 (br. s., 1 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.6, 130.3, 128.9, 127.8, 127.0, 65.7, 58.6, 44.3, 27.9; **HRMS-APCI** (m/z): [M+H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>17</sub>ON<sub>4</sub>, 233.13969; found, 233.13983.


## 2 Synthesis of 3-methyl-3-(5-phenyl-2H-tetrazol-2-yl)butanoic acid (**4b**)



Iodobenzene diacetate (425.2 mg, 1.32 mmol 2.2 eq.), TEMPO (18.8 mg, 0.12 mmol 20 mol%), NaHCO<sub>3</sub>(100.8 mg, 1.20 mmol, 2.0 eq.), and **4a** (144.8 g, 0.60 mmol) were added in a flask. To this mixture was added MeCN : H<sub>2</sub>O (0.75 mL : 0.75 mL). The reaction was cooled to 0 °C and stirred for 2 h, then warmed to room temperature and stirred for an additional 2 h. The reaction mixture was concentrated under reduced pressure.<sup>[4]</sup> The crude reaction mixture was initially purified by flash column chromatography (CH/EE/formic acid = 4/1/0.02, R<sub>f</sub> = 0.20) to give **4b** (145.5 mg, 99 % yield) as a white solid.

**m.p.:** 126-128 °C; **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 10.77 (br. s., 1 H), 8.08 - 8.20 (m, 2 H), 7.41 - 7.53 (m, 3 H), 3.19 (s, 2 H), 1.91 (s, 6 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 174.6, 164.7, 130.3, 128.9, 127.7, 127.0, 64.0, 45.3, 27.6; **HRMS-APCI** (m/z): [M+H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>15</sub>ON<sub>4</sub>, 274.11895; found, 274.11893.


### 3 Synthesis of (*R*)-2-cyclohexyl-2-(5-phenyl-2*H*-tetrazol-2-yl)ethanol (**4c**)



**1a** (134.2 mg, 0.50 mmol) was dissolved in MeOH : CH<sub>2</sub>Cl<sub>2</sub> (5 ml : 5 ml, 0.05 M) and cooled to -78 °C. Ozone was bubbled through the solution until a blue color persisted in the solution (approximately 5 min). Then, NaBH<sub>4</sub> (94.6 mg, 2.50 mmol, 5 eq.) was added to the reaction mixture. The cold bath was removed, and the reaction was allowed to gradually warm to room temperature. After stirring for two hours at room temperature, the reaction was quenched by adding 1 M HCl (15 mL). The resulting organic layer was separated. The aqueous layer was brought to neutral pH by addition of saturated aqueous NaHCO<sub>3</sub> and extracted with EtOAc (2 x 30 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated.<sup>[4]</sup> The resulting crude product was purified by flash column silica gel chromatography (CH/EE = 5/1, R<sub>f</sub> = 0.20) to give **4c** (120.8 mg, 0.44 mmol, 89%) as a white solid.

**m.p.:** 88-90 °C; **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.09 - 8.18 (m, 2 H), 7.44 - 7.52 (m, 3 H), 4.73 (ddd, J=8.6, 7.3, 3.0 Hz, 1 H), 4.30 (dd, J=12.3, 7.3 Hz, 1 H), 4.10 (dd, J=12.3, 3.0 Hz, 1 H), 2.49 (br. s, 1 H), 2.16 (ddddd, J=11.6, 11.6, 8.3, 3.4, 3.4 Hz, 1 H), 1.88 - 1.97 (m, 1 H), 1.75 - 1.85 (m, 1 H), 1.59 - 1.73 (m, 2 H), 0.94 - 1.38 (m, 6 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 165.0, 130.4, 129.0, 127.4, 127.0, 71.7, 62.2, 39.1, 29.8, 29.4, 26.1, 25.9, 25.7; **HRMS-APCI** (m/z): [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>21</sub>ON<sub>4</sub>, 273.17099; found, 273.17099. **HPLC** (CHIRALCEL® AD-3, n-heptane / iPrOH = 90:10, 1 mL/min) t<sub>R</sub> = 8.27 min (minor), t<sub>R</sub> = 9.70 min (major), 85% ee (**R**); [α]<sub>D</sub><sup>25</sup> = + 10.8 (c = 0.665, CH<sub>2</sub>Cl<sub>2</sub>).

#### 4 Synthesis of (S)-4-cyclohexyl-4-(5-phenyl-2*H*-tetrazol-2-yl)butanal (**4d**)




[Rh(CO)<sub>2</sub>acac] (0.3 mg, 1 μmol, 0.5 mol%) and 6-DPPon (5.6 mg, 0.02 mmol, 10 mol%) were added in a high-pressure autoclave and dissolved in toluene (2.0 mL 0.01 M) before **1a** (53.7 mg, 0.2 mmol, 1.0 equiv) was added. The mixture was stirred at 80 °C under CO/H<sub>2</sub> (20 bar) for 20 hours. The reaction mixture was filtrated over a short silica column, rinsed with ethyl acetate and concentrated by rotary evaporation.<sup>[6]</sup> The resulting crude product was purified by flash column silica gel chromatography (CH/EE = 10/1, R<sub>f</sub> = 0.11) to give **4d** (41.8 mg, 70%) as a colorless oil.

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 9.69 (s, 1 H), 8.14 - 8.18 (m, 2 H), 7.45 - 7.52 (m, 3 H), 4.65 (ddd, J=10.5, 8.1, 3.7 Hz, 1 H), 2.33 - 2.50 (m, 2 H), 2.20 - 2.33 (m, 2 H), 1.91 - 2.07 (m, 2 H), 1.76 - 1.84 (m, 1 H), 1.60 - 1.73 (m, 2 H), 0.94 - 1.36 (m, 6 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 200.3, 165.1, 130.4, 129.0, 127.6, 127.0, 69.5, 42.5,

40.2, 29.8, 29.3, 26.1, 25.9, 25.7, 23.9; **HRMS-APCI** (m/z): [M+H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>ON<sub>4</sub>Na, 321.16858; found, 321.16867.

**5 Synthesis of (S)-4-cyclohexyl-4-(5-phenyl-2*H*-tetrazol-2-yl)butan-1-ol (**4e**)**





**4d** (15.0 mg, 0.05 mmol, 1.0 equiv) was dissolved in dry MeOH (1.0 ml, 0.05) and cooled to 0 °C. Then NaBH<sub>4</sub> (3.8 mg, 0.1 mmol, 2.0 equiv) was added to the reaction vessel. The reaction mixture was stirred for 15 min at 0 °C. Then, the ice bath was removed and the solution was stirred overnight at room temperature. The reaction mixture was quenched by adding saturated aqueous NH<sub>4</sub>Cl Solution (5 ml) and the resulting solution was extracted several times with Et<sub>2</sub>O. The organic layers were combined, dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product was purified by flash column silica gel chromatography (CH/EE = 5/1, R<sub>f</sub> = 0.09) to give **4e** (13.1 mg, 87 % yield) as a colorless oil.

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ = 8.19 - 8.14 (m, 2 H), 7.52 - 7.43 (m, 3 H), 4.70 - 4.61 (m, 1 H), 3.68 - 3.54 (m, 2 H), 2.28 - 2.10 (m, 2 H), 2.04 - 1.90 (m, 2 H), 1.83 - 1.74 (m, 1 H), 1.72 - 1.61 (m, 2 H), 1.50 - 1.38 (m, 2 H), 1.35 - 0.94 (m, 7 H); **<sup>13</sup>C NMR** (101 MHz, CDCl<sub>3</sub>) δ = 164.9, 130.3, 128.9, 127.8, 127.0, 70.4, 62.1, 42.6, 30.0, 29.3, 29.1, 28.0, 26.2, 26.0, 25.8; **HRMS-ESI** (m/z): [M+Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>ON<sub>4</sub>Na, 323.18423; found, 323.18448. **HPLC** (CHIRALCEL® AD-3, *n*-heptane / <sup>i</sup>PrOH = 93:7, 1 mL/min) t<sub>R</sub> = 12.03 min (minor), t<sub>R</sub> = 12.99 min (major), 87% ee (*S*); [α]<sub>D</sub><sup>25</sup> = + 8.1 (c = 0.520, CH<sub>2</sub>Cl<sub>2</sub>).


## Deuterium Labeling Experiment

### Rhodium catalyzed coupling of [D]phenyltetrazole with cyclohexylallene

Experiment adapted the standard scope conditions, product **5** was isolated as a colorless oil, yield 59% (37.7 mg).



## Proposed Mechanism





## References


- 1 Demko, Z. P.; Sharpless, K. B. *J. Org. Chem.* **2001**, *66*, 7945-7950.
- 2 a) Taherirastgar, F.; Brandsma, L. *Synth. Commun.* **1997**, *27*, 4035–4040; b) Xu, K.; Thieme, N.; Breit, B. *Angew. Chem. Int. Ed.* **2014**, *53*, 2162-2165; c) Kuang, J.; Ma, S. *J. Org. Chem.* **1999**, *74*, 1763-1765; d) Danheiser, R. L.; Tsai, Y.; Fink, D. M. *Org. Synth.* **1988**, *66*, 1-7.
- 3 Deuterium exchange according to: T. Sakaizumi, H. Kikuchi, O. Ohashi, I. Yamaguchi, *Bull. Chem. Soc. Jpn.*, **1987**, *60*, 3903-3909.
- 4 L. M. Stanley, J. F. Hartwig, *J. Am. Chem. Soc.* **2009**, *131*, 8971-8983.
- 5 U. Uriá, J. L. Vicario, D. Bad á, L. Carrillo, *Chem. Sommun.*, 2007, 2509-2511.
- 6 W. Seiche, A. Schuschkowski, B. Breit, *Adv. Synth. Catal.* **2005**, *347*, 1488–1494.

## **<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra**


**(S)-2-(1-cyclohexylallyl)-5-phenyl-2*H*-tetrazole (**1a**)**




**(S)-2-(1-cyclohexylallyl)-5-(p-tolyl)-2*H*-tetrazole (**1b**)**




(*S*)-2-(1-cyclohexylallyl)-5-(4-fluorophenyl)-2*H*-tetrazole (**1c**)





(S)-5-(4-chlorophenyl)-2-(1-cyclohexylallyl)-2*H*-tetrazole (**1d**)




(S)-5-(4-bromophenyl)-2-(1-cyclohexylallyl)-2*H*-tetrazole (**1e**)




(*S*)-3-(2-(1-cyclohexylallyl)-2*H*-tetrazol-5-yl)aniline (**1f**)




**(S)-2-(1-cyclohexylallyl)-5-(naphthalen-2-yl)-2*H*-tetrazole (**1g**)**




**(S)-2-(1-cyclopentylallyl)-5-phenyl-2*H*-tetrazole (**1h**)**




*(R)*-2-(oct-1-en-3-yl)-5-phenyl-2*H*-tetrazole (**1i**)




*(R)*-5-phenyl-2-(6-phenylhex-1-en-3-yl)-2*H*-tetrazole (**1j**)




(*R*)-methyl 5-(5-phenyl-2*H*-tetrazol-2-yl)hept-6-enoate (**1k**)




*(R)*-2-(4-(5-phenyl-2*H*-tetrazol-2-yl)hex-5-en-1-yl)isoindoline-1,3-dione (**1l**)




(S)-2-(2-(adamantan-1-yl)but-3-en-2-yl)-5-phenyl-2*H*-tetrazole (**2a**)




*(R)*-2-((tert-butyldimethylsilyl)oxy)-2-methylbut-3-en-2-yl)-5-phenyl-2*H*-tetrazole (**2b**)




(S)-5-phenyl-2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazole (**2c**)




**(S)-5-(p-tolyl)-2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazole (**2d**)**




(S)-5-(4-bromophenyl)-2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazole (**2e**)




(S)-3-(2-(2-(trimethylsilyl)but-3-en-2-yl)-2*H*-tetrazol-5-yl)aniline (**2f**)




2-(2-methylbut-3-en-2-yl)-5-phenyl-2*H*-tetrazole (**3**)




3-methyl-3-(5-phenyl-2H-tetrazol-2-yl)butan-1-ol (**4a**)




3-methyl-3-(5-phenyl-2H-tetrazol-2-yl)butanoic acid (**4b**)




*(R)*-2-cyclohexyl-2-(5-phenyl-2*H*-tetrazol-2-yl)ethanol (**4c**)



(S)-4-cyclohexyl-4-(5-phenyl-2H-tetrazol-2-yl)butanal (**4d**)




(S)-4-cyclohexyl-4-(5-phenyl-2H-tetrazol-2-yl)butan-1-ol (**4e**)



## Chromatogram :L-C2 Hep\_IPA 100\_1 0,5ml 220nm

Method : L-C2 Hep\_IPA 100\_1 0,5ml 220nm  
User : Timm Bury  
07.04.2015 08:40:12  
Timm Bury  
TiBu-199-l-chir1


Acquired : 07.04.2015 08:40:12  
Processed : 08.04.2015 05:08:15  
Printed : 08.04.2015 05:08:47  
System 2 (RP / NP Anlage)



## Chromatogram :L-C2 Hep\_IPA 100\_1 0,5ml 220nm

Method : L-C2 Hep\_IPA 100\_1 0,5ml 220nm  
User : Timm Bury  
07.04.2015 08:18:35  
Timm Bury  
TiBu-199-rac1

Acquired : 07.04.2015 08:18:35  
Processed : 08.04.2015 05:03:24  
Printed : 08.04.2015 05:04:03  
System 2 (RP / NP Anlage)



**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 07.04.14 14:13

Reported: 08.04.15 11:04  
Processed: 07.04.14 14:45

Data Path: C:\PROGRAMME\HSM\Rainondi\DATA\0032\

Processing Method: AD-3 Hep/IPA 400/1 1ml 245nm

System(acquisition): Sys 2

Series:0032

Application: Rainondi

Vial Number: 1

Sample Name: wil01086-c


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: AD-3 Hep/IPA 400/1 1ml 245nm

Column Type: WHELK-02

Developed by: fahrenbach

Pump A Type: L-7100

Solvent A: Heptan

Solvent B: i-Propanol

Solvent C: Hep/IPA 100/1

Solvent D: Äthanol

Method Description: n-Heptan / IPA 400/1, 245nm, 1ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	2,23	0,008	1322	BB
2	9,57	0,039	6279	BB
3	10,74	0,018	2817	BB
4	19,67	0,018	2957	BB
5	21,51	4,501	722746	BB
6	23,26	95,416	15321921	BB
		100,000	16058042	

Peak rejection level: 0

**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 07.04.14 13:35

Reported: 08.04.15 11:04  
Processed: 07.04.14 14:10

Data Path: C:\PROGRAMME\HSM\Rainondi\DATA\0031\

Processing Method: AD-3 Hep/IPA 400/1 1ml 245nm

System(acquisition): Sys 2

Series:0031

Application: Rainondi

Vial Number: 1

Sample Name: kx-5065e rac


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: AD-3 Hep/IPA 400/1 1ml 245nm

Column Type: WHELK-02

Developed by: fahrenbach

Pump A Type: L-7100

Solvent A: Heptan

Solvent B: i-Propanol

Solvent C: Hep/IPA 100/1

Solvent D: Äthanol

Method Description: n-Heptan / IPA 400/1, 245nm, 1ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA

Calculation Method: AREA%


No.	RT	Area %	Area	BC
1	9,28	0,048	8619	BB
2	18,42	0,060	10665	BB
3	21,01	50,512	8983621	BV
4	23,56	49,379	8782168	VB
		100,000	17785073	

Peak rejection level: 0

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01089-d ee {Data Description}

E:\EZDatenOC\Raidondi\Method\L-C4, Hep\_IPA 600\_1, 22°C, 1ml.met


Vial: 194 Injection Volume (μl): 2  
Run Time: 07.04.2014 15:51:49 Analysis Time: 08.04.2015 11:00:38

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	10,433	2,657	225
2	14,920	90,382	241
3	23,147	6,960	241

DAD-250 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	14,920	92,585	241
2	23,147	7,415	241



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

kx-5068-b rac {Data Description}

E:\EZDatenOC\Raidondi\Method\L-C4, Hep\_IPA 600\_1, 22°C, 1ml.met

Vial: 193 Injection Volume (μl): 2  
Run Time: 07.04.2014 15:17:35 Analysis Time: 08.04.2015 11:01:08

1: 238 nm, 4 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,113	4,151	236
2	6,727	0,187	272
3	10,073	0,317	238
4	10,893	0,199	236
5	14,873	47,783	241
6	22,700	47,364	241

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,113	2,687	236
2	6,727	0,881	272
3	10,493	3,884	274
4	14,873	46,537	241
5	22,700	46,012	241

DAD-250 nm  
Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,113	2,455	236
2	6,727	0,208	272
3	10,073	0,325	238
4	10,900	0,180	235
5	14,873	48,679	241
6	22,700	48,153	241



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

## wil01087-b ee {Data Description}

E:\EZDatenOC\Raidondi\Method\L-C4, Hep\_IPA 600\_1, 22°C, 1ml.met

Vial: 192 Injection Volume (μl): 2  
Run Time: 07.04.2014 14:42:10 Analysis Time: 08.04.2015 11:00:14

## 1: 238 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	4,233	0,212	204
2	5,400	0,284	201
3	14,767	92,904	203
4	21,387	6,599	203


## Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	10,447	3,940	226
2	14,767	89,868	203
3	21,387	6,089	203
4	29,647	0,103	212

## DAD-250 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	4,233	0,164	204
2	5,400	0,240	201


3	14,767	93,019	203
4	21,387	6,578	203



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

kx-5065-g rac {Data Description}

E:\EZDatenOC\Raidondi\Method\L-C4, Hep\_IPA 600\_1, 22°C, 1ml.met


Vial: 191 Injection Volume (μl): 2  
Run Time: 07.04.2014 14:13:21 Analysis Time: 08.04.2015 10:59:50

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,020	0,599	290
2	6,700	0,083	276
3	10,420	4,083	230
4	14,753	47,685	202
5	21,287	47,551	202

DAD-250 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	6,707	0,093	276
2	8,987	0,101	265
3	10,167	0,174	247
4	11,393	0,117	250
5	14,753	49,823	202
6	21,287	49,693	202



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

wil01088-b ee {Data Description}

E:\EZDatenOC\Raidondi\Method\L-C4, Hep\_IPA 1000\_1, 22°C, 1ml.met

Vial: 196 Injection Volume (μl): 2  
Run Time: 08.04.2014 11:57:26 Analysis Time: 08.04.2015 10:58:12

## 1: 238 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,033	0,260	279
2	7,140	0,238	255
3	10,033	0,445	203
4	14,767	0,140	227
5	31,873	92,911	204
6	47,333	5,966	204
7	53,053	0,039	276


## Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	14,873	3,809	226
2	31,880	90,730	204
3	47,360	5,460	204

## DAD-253 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
------	----------------	--------------	------------

1	7,147	0,170	255
2	10,040	0,335	203
3	31,873	93,509	204
4	47,320	5,986	204




Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

kx-5065-h rac


{Data Description}

E:\EZDatenOC\Raidondi\Method\L-C4, Hep\_IPA 1000\_1, 22°C, 1ml.met

Vial: 195      Injection Volume (µl): 2  
 Run Time: 08.04.2014 10:59:24      Analysis Time: 08.04.2015 10:57:39



Pk #	Retention Time	Area Percent	Lambda Max
1	13,980	0,112	277
2	21,780	0,124	260
3	27,713	0,096	259
4	30,913	49,866	204
5	44,480	49,801	204




DAD-253 nm  
 Results

Albert-Ludwigs-Universität Freiburg  
 Institut für Organische Chemie und Biochemie

wil01094-3 {Data Description}  
 E:\EZDatenOC\Raidondi\Method\OD-H, Hep\_IPA 80\_20, 22°C, 1ml.met

Vial: 192 Injection Volume (μl): 2  
 Run Time: 05.02.2014 11:14:33 Analysis Time: 08.04.2015 10:56:10




DAD-228 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	4,007	0,024	205
2	9,567	0,052	205
3	10,987	0,039	205
4	12,433	10,704	228
5	14,540	89,182	228

Spectrum Max Plot Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	4,007	0,106	205
2	12,433	9,862	228
3	14,540	90,032	228

1: 210 nm, 4 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	4,000	0,166	206
2	12,433	10,747	228

3 14,540 89,086 228




Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

kx-5065-s rac

{Data Description}

E:\EZDatenOC\Raidondi\Method\OD-H, Hep\_IPA 80\_20, 22°C, 1ml.met

Vial: 191      Injection Volume (µl): 2  
Run Time: 05.02.2014 10:36:31      Analysis Time: 08.04.2015 10:56:46


Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	3,987	0,432	205
2	9,920	0,214	204
3	12,413	50,136	228
4	14,573	49,218	228

DAD-228 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	5,100	0,229	204

2	7,120	0,426	204
3	9,907	0,253	204
4	12,413	49,250	228
5	14,573	49,843	228



19


wil01151

Page 1 of 2

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01151 {Data Description}

E:\EZDatenOC\Raidondi\Method\OD-3, Hep\_IPA 300\_1, 22°C, 0,5ml.met

Vial: 192 Injection Volume (µl): 2  
Run Time: 14.05.2014 15:32:47 Analysis Time: 14.05.2014 16:03:57

DAD-241 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	4,013	0,018	295
2	5,773	0,012	288
3	23,913	92,461	242
4	26,793	7,350	242
5	29,247	0,159	241

1: 210 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	23,913	92,534	242


wil01151

Page 1 of 2

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01151 {Data Description}

E:\EZDatenOC\Raidondi\Method\OD-3, Hep\_IPA 300\_1, 22°C, 0,5ml.met

Vial: 191 Injection Volume (µl): 2  
Run Time: 14.05.2014 14:55:10 Analysis Time: 08.04.2015 16:01:37

1: 210 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	23,147	49,752	242
2	25,800	50,248	242

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	23,147	49,752	242
2	25,800	50,248	242

DAD-241 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	23,147	49,754	242
2	25,800	50,246	242

**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 03.07.14 11:20

Reported: 08.04.15 11:05  
Processed: 03.07.14 11:35

Data Path: C:\PROGRAMME\HSM\Rainondi\DATA\0052\

Processing Method: AD-3 Hep/IPA 98/2 1ml 240nmAS

System(acquisition): Sys 2

Series:0052

Application: Rainondi

Vial Number: 114

Sample Name: wil01154 ee


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: AD-3 Hep/IPA 98/2 1ml 240nmAS

Column Type: WHELK-02

Developed by: fehrenbach

Pump A Type: L-7100

Solvent A: Heptan

Solvent B: i-Propanol

Solvent C: Hep/IPA 100/1

Solvent D: Äthanol

Method Description: n-Heptan / IPA 98/2, 240nm, 1ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	2,50	0,013	1325	BB
2	3,45	0,059	6046	BB
3	4,79	0,015	1484	BB
4	5,27	0,039	4000	BB
5	6,29	0,008	781	BB
6	8,60	5,110	520756	BB
7	9,37	94,756	9656753	BB
		100,000	10191145	

Peak rejection level: 0

Channel 1 Noise: Not Measured

Channel 1 Drift: Not Measured

## Configuration parameters:

Interface Module: D-7000

Channel 1 Detector: L-7400

Column Oven: None

Pump A: L-7100

Number of Solvents pump A: 4

External Instrument Software: None

Gradient Mode: Low

Channel 2 Detector: None

Autosampler: L-7250

Pump B: None

Number of Solvents pump B: 1

Column Name: WHELK-02

## Method Information:

Method Name: AD-3 Hep/IPA 98/2 1ml 240nmAS

Developed by: fehrenbach

## Description:

n-Heptan / IPA 98/2, 240nm, 1ml/min

## Method History

Date User Comment

01.10.12 15:35 test Method originated from OD3 n-Heptan/IPA 90/10 254nm

01.10.12 15:35 test

## Pump Setup:

Main Pump (A) Pressure Limit: 10 to 150 bar

## Pump A (L-7100):

Solvent A: Heptan

Solvent B: i-Propanol

Solvent C: Hep/IPA 100/1

Solvent D: Äthanol

## Pump A (L-7100):

## Pump Solvent and Event Table

Time (min)	%Hepta	%i-Pro	%Hep/I	%Äthan	Flow (ml/min)	Event 1	Event 2	Event 3	Event 4
0,0	98,0	2,0	0,0	0,0	1,000				

## Autosampler Setup (L-7250):

Syringe Speed: 5

Needle Down Speed: Fast

Syringe Volume: 500 ul

Injection Method: Cut

Lead Volume: 100,00 ul

Rear Volume: 100,00 ul

Needle Wash Strokes: 1

Needle Wash Speed: 5

Injection Port Wash Stroke: 1

Injection Port Wash Speed: 5

## Channel 1 Detector (L-7400):

Response Time: 2.0 sec

Absorbance Range: 1 AU

Offset: 0,000 AU

Stop Time: 14,00 min

Auto Data Sampling Mode: YES

Initial Sampling Period: 200 msec

Doubling Time: 10,00 min

## Detector Table

Time(min) WL(nm) Baseline

0,0 240 Auto Zero

## Sampling Period Table

**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 02.07.14 16:42

Reported: 08.04.15 11:05  
Processed: 02.07.14 16:55

Data Path: C:\PROGRAMME\HSM\Rainondi\DATA\0047\

Processing Method: AD-3 Hep/IPA 98/2 1ml 240nmAS

System(acquisition): Sys 2

Series:0047  
Vial Number: 106  
Vial Type: UNK  
Volume: 1,0 ul


Application: Rainondi

Sample Name: wil01153

Injection from this vial: 1 of 1

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: AD-3 Hep/IPA 98/2 1ml 240nmAS

Column Type: WHELK-02

Developed by: fehrenbach

Pump A Type: L-7100

Solvent A: Heptan

Solvent B: i-Propanol

Solvent C: Hep/IPA 100/1

Solvent D: Äthanol

Method Description: n-Heptan / IPA 98/2, 240nm, 1ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	2,37	0,016	1763	BB
2	3,03	0,008	870	BB
3	3,48	0,048	5372	BB
4	3,85	0,015	1677	BB
5	4,59	0,212	23552	BB
6	5,33	0,007	788	BB
7	8,85	49,877	5528856	BV
8	9,76	49,816	5522054	VB
		100,000	11084932	

Peak rejection level: 0

Channel 1 Noise: Not Measured

Channel 1 Drift: Not Measured

## Configuration parameters:

Interface Module: D-7000

Channel 1 Detector: L-7400

Column Oven: None

Pump A: L-7100

Number of Solvents pump A: 4

External Instrument Software: None

Gradient Mode: Low

Channel 2 Detector: None

Autosampler: L-7250

Pump B: None

Number of Solvents pump B: 1

Column Name: WHELK-02

## Method Information:

Method Name: AD-3 Hep/IPA 98/2 1ml 240nmAS

Developed by: fehrenbach

## Description:

n-Heptan / IPA 98/2, 240nm, 1ml/min

## Method History

Date	User	Comment
01.10.12 15:35	test	Method originated from OD3 n-Heptan/IPA 90/10 254nm
01.10.12 15:35	test	

## Pump Setup:

Main Pump (A) Pressure Limit: 10 to 150 bar

## Pump A (L-7100):

Solvent A: Heptan

Solvent B: i-Propanol

Solvent C: Hep/IPA 100/1

Solvent D: Äthanol

## Pump A (L-7100):

## Pump Solvent and Event Table

Time (min)	%Hepta	%i-Pro	%Hep/I	%Äthan	Flow (ml/min)	Event 1	Event 2	Event 3	Event 4
0,0	98,0	2,0	0,0	0,0	1,000				

## Autosampler Setup (L-7250):

Syringe Speed: 5

Needle Down Speed: Fast

Syringe Volume: 500 ul

Injection Method: Cut

Lead Volume: 100,00 ul

Rear Volume: 100,00 ul

Needle Wash Strokes: 1

Needle Wash Speed: 5

Injection Port Wash Stroke: 1

Injection Port Wash Speed: 5

## Channel 1 Detector (L-7400):

Response Time: 2.0 sec

Absorbance Range: 1 AU

Offset: 0,000 AU

Stop Time: 17,00 min

Auto Data Sampling Mode: YES

Initial Sampling Period: 200 msec

Doubling Time: 10,00 min

## Detector Table

Time(min)	WL(nm)	Baseline
0,0	240	Auto Zero


## Sampling Period Table

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01178ee {Data Description}

E:\EZDatenOC\KunXu\Method\AD-3, Hept\_IPA, 200\_1,200-400nm, 22°C, 1  
ml.met

Vial: 8 Injection Volume (μl): 1  
Run Time: 12.09.2014 19:13:04 Analysis Time: 08.04.2015 10:47:33



1: 230 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,073	0,172	385
2	3,947	0,021	248
3	4,827	0,075	240
4	5,580	0,080	269
5	6,787	0,035	232
6	7,593	91,502	201
7	8,133	7,780	200
8	9,167	0,144	233
9	10,647	0,051	232
10	11,367	0,088	237
11	12,153	0,052	238

2: 250 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,073	0,025	385
2	3,947	0,023	248
3	4,827	0,034	240
4	5,573	0,082	269

5	6,793	0,029	232
6	7,147	0,035	232
7	7,593	91,759	201
8	8,140	7,800	200
9	9,180	0,070	233
10	10,213	0,018	236
11	10,640	0,029	232
12	11,393	0,061	237
13	12,207	0,035	238

## 4: 210 nm, 4 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	1,236	385
2	2,360	0,020	385
3	3,940	0,034	248
4	4,827	0,039	240
5	5,173	0,009	384
6	5,573	0,086	269
7	6,047	0,008	230
8	6,780	0,041	232
9	7,160	0,043	234
10	7,593	90,412	201
11	8,133	7,752	200
12	9,180	0,139	233
13	9,587	0,014	234
14	10,187	0,036	236
15	10,660	0,044	233
16	11,367	0,067	237
17	12,207	0,021	238

## Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	1,187	385
2	7,593	90,999	201
3	8,133	7,813	200

## DAD-241 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	0,031	385
2	7,593	92,040	201
3	8,133	7,739	200
4	11,373	0,048	237
5	12,193	0,048	238
6	13,193	0,058	239
7	13,700	0,029	239
8	14,647	0,008	239




Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01177 rac {Data Description}

E:\EZDatenOC\KunXu\Method\AD-3, Hept\_IPA, 200\_1,200-400nm, 22°C, 1 ml.met

Vial: 3 Injection Volume (µl): 1  
Run Time: 12.09.2014 15:42:32 Analysis Time: 08.04.2015 10:48:06



1: 230 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	0,090	276
2	6,240	0,063	233
3	6,947	0,280	236
4	7,340	0,614	240
5	7,647	0,093	235
6	7,907	49,882	201
7	8,493	48,978	201

2: 250 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,073	0,013	276
2	2,360	0,002	276
3	4,053	0,004	277
4	4,507	0,027	233
5	4,807	0,003	276
6	6,947	0,280	236
7	7,340	0,613	240
8	7,687	0,161	237

9	7,913	49,848	201
10	8,493	49,047	201
11	9,773	0,003	232

**4: 210 nm, 4 nm Results**


Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	0,663	276
2	2,360	0,010	276
3	6,947	0,297	236
4	7,340	0,639	240
5	7,660	0,118	236
6	7,907	49,554	201
7	8,493	48,719	201

**Spectrum Max Plot Results**

Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	0,654	276
2	6,947	0,336	236
3	7,333	0,661	240
4	7,907	49,613	201
5	8,493	48,736	201

**DAD-241 nm Results**

Pk #	Retention Time	Area Percent	Lambda Max
1	4,060	0,003	277
2	4,493	0,024	233
3	5,587	0,013	275
4	6,240	0,058	233
5	6,947	0,278	236
6	7,340	0,608	240
7	7,907	50,000	201
8	8,493	49,015	201



**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 24.09.14 15:00

Reported: 08.04.15 11:06  
 Processed: 24.09.14 16:01

Data Path: D:\HSM\KunXu\DATA\0701\

Processing Method: L-C2 Hep/IPA 200/1 240nm 0,5ml

System(acquisition): Sys 1

Series:0701

Application: KunXu

Vial Number: 1

Sample Name: wil01109-b ee


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: L-C2 Hep/IPA 200/1 240nm 0,5ml  
 Column Type: Chiralpak AD-H Developed by: fahrenbach  
 Pump A Type: L-7100  
 Solvent A: Heptan Solvent B: i-Propanol  
 Solvent C: Hep/IPA 100/1 Solvent D: Äthanol  
 Method Description: n-Heptan/IPA 200/1, 240nm, 0,5ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA  
 Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	4,43	0,016	2457	BB
2	7,53	0,036	5629	BB
3	16,35	1,020	157454	BB
4	21,91	0,059	9168	BB
5	27,57	93,749	14471544	BB
6	51,47	5,066	782067	BB
7	54,90	0,053	8154	BB
		100,000	15436473	

Peak rejection level: 0

**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 24.09.14 12:58

Reported: 08.04.15 11:06  
 Processed: 24.09.14 14:59

Data Path: D:\HSM\KunXu\DATA\0700\

Processing Method: L-C2 Hep/IPA 200/1 240nm 0,5ml

System(acquisition): Sys 1

Series:0700

Application: KunXu

Vial Number: 1

Sample Name: kx-5067-a rac


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: L-C2 Hep/IPA 200/1 240nm 0,5ml  
 Column Type: Chiralpak AD-H Developed by: fahrenbach  
 Pump A Type: L-7100  
 Solvent A: Heptan Solvent B: i-Propanol  
 Solvent C: Hep/IPA 100/1 Solvent D: Äthanol  
 Method Description: n-Heptan/IPA 200/1, 240nm, 0,5ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA  
 Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	4,16	0,011	825	BB
2	13,23	0,185	14020	BB
3	14,61	0,055	4164	BB
4	20,07	0,430	32534	BB
5	22,31	0,228	17224	BB
6	27,87	48,680	3681514	MC
7	29,28	1,360	102872	MC
8	33,37	0,152	11466	BB
9	38,55	0,143	10841	BB
10	55,51	48,756	3687284	MC
		100,000	7562744	


Peak rejection level: 0

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01173ee {Data Description}

E:\EZDatenOC\KunXu\Method\AD-3, Hept\_IPA, 200\_1,200-400nm, 22°C, 1  
ml.met

Vial: 7 Injection Volume (μl): 1  
Run Time: 12.09.2014 17:59:55 Analysis Time: 08.04.2015 10:45:57



2: 250 nm, 4 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,073	0,064	391
2	7,633	0,012	234
3	8,160	0,030	234
4	11,493	0,192	236
5	56,027	7,669	240
6	60,807	92,033	200

4: 210 nm, 4 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,073	3,330	391
2	56,047	7,452	200
3	57,540	0,027	238
4	60,800	88,296	200
5	66,367	0,873	239
6	67,260	0,023	239

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,073	3,353	391
2	56,040	6,531	200
3	60,807	90,116	200

DAD-241 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	0,138	390
2	56,007	7,944	200
3	58,127	0,065	239
4	60,807	90,495	200
5	63,553	0,022	239
6	64,500	0,025	239
7	66,420	1,281	239
8	67,767	0,030	239






Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

wil01174 rac {Data Description}

E:\EZDatenOC\KunXu\Method\AD-3, Hept\_IPA, 200\_1,200-400nm, 22°C, 1  
ml.met

Vial: 5 Injection Volume ( $\mu$ l): 1  
Run Time: 12.09.2014 16:23:37 Analysis Time: 08.04.2015 10:46:35




Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,067	0,511	268
2	55,020	49,763	201
3	59,700	49,726	201

DAD-241 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	15,407	0,042	232
2	39,740	0,077	233
3	48,460	0,025	263
4	55,013	48,652	201
5	57,540	0,474	237
6	59,707	49,553	201
7	65,367	1,086	236
8	67,700	0,081	234
9	69,400	0,008	261



**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 07.10.14 13:03

Reported: 08.04.15 11:07  
Processed: 07.10.14 13:45

Data Path: D:\HSM\KunXu\DATA\0723\

Processing Method: L-C2 Hep/IPA 50/50 235nm 0,5ml

System(acquisition): Sys 1

Series:0723

Application: KunXu

Vial Number: 1

Sample Name: wil01097-B ee


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: L-C2 Hep/IPA 50/50 235nm 0,5ml  
Column Type: Chiralpak AD-H      Developed by: fehrenbach  
Pump A Type: L-7100  
Solvent A: Heptan      Solvent B: i-Propanol  
Solvent C: Hep/IPA 100/1      Solvent D: Äthanol  
Method Description: n-Heptan/IPA 50/50, 235nm, 0,5ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA  
Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	3,46	0,049	5693	BV
2	3,73	0,041	4752	VV
3	3,87	0,078	9154	VV
4	4,09	0,207	24194	VV
5	4,43	0,219	25646	VB
6	5,25	0,087	10200	BB
7	6,67	0,039	4522	BV
8	7,00	0,028	3258	VV
9	7,46	0,027	3133	VB
10	8,30	0,005	528	BB
11	8,70	0,005	546	BB
12	9,45	0,009	1060	BB
13	10,22	0,007	825	BB
14	10,76	0,025	2978	BB
15	11,47	0,008	896	BB
16	12,09	0,072	8385	BB

D-7000 HSM: KunXu	Series: 0723	Report: modified	System: Sys 1
17	14,12	6,945	811917 BB
18	16,50	0,042	4938 BB
19	19,19	0,009	1030 BB
20	21,29	0,007	824 BB
21	23,78	0,038	4446 BB
22	26,35	92,054	10762364 BB
		100,000	11691289

Peak rejection level: 0

**Universität Freiburg**  
**Inst. für Organische Chemie und**  
**Biochemie**

Analyzed: 07.10.14 12:02

Reported: 08.04.15 11:07

Data Path: D:\HSM\KunXu\DATA\0722\

Processed: 07.10.14 12:58

Processing Method: L-C2 Hep/IPA 50/50 235nm 0,5ml

System(acquisition): Sys 1

Series:0722

Application: KunXu

Vial Number: 1

Sample Name: kx-5067-D rac


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description:

Chrom Type: HPLC Channel : 1



Acquisition Method: L-C2 Hep/IPA 50/50 235nm 0,5ml  
Column Type: Chiralpak AD-H      Developed by: fahrenbach  
Pump A Type: L-7100  
Solvent A: Heptan      Solvent B: i-Propanol  
Solvent C: Hep/IPA 100/1      Solvent D: Äthanol  
Method Description: n-Heptan/IPA 50/50, 235nm, 0,5ml/min

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA  
Calculation Method: AREA%

No.	RT	Area %	Area	BC
1	3,57	0,075	11409	BV
2	3,71	0,143	21845	VV
3	3,85	0,141	21621	VV
4	4,14	0,224	34307	VV
5	4,22	0,132	20174	VV
6	4,39	0,424	64826	VB
7	5,30	0,156	23915	BB
8	5,90	0,063	9582	BV
9	6,66	0,283	43352	VB
10	7,97	0,061	9375	BV
11	8,86	0,008	1279	VB
12	9,75	0,005	720	BB
13	10,83	0,005	693	BB
14	11,43	0,036	5487	BV
15	11,98	0,032	4937	VB
16	13,27	0,214	32663	BV

D-7000 HSM: KunXu	Series: 0722	Report: modified	System: Sys 1
17	14,10	46,729	7148917 MC
18	14,99	2,088	319372 MC
19	16,15	0,101	15500 TVB
20	17,24	1,053	161037 TVB
21	19,39	0,039	5923 TVB
22	20,17	0,230	35180 TVB
23	21,23	0,125	19154 TVB
24	23,75	0,247	37735 BV
25	26,69	47,141	7211922 VV
26	34,12	0,212	32500 MC
27	38,43	0,035	5316 VB
		100,000	15298741


Peak rejection level: 0

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

TiBu-156 ee {Data Description}

E:\EZDatenOC\Thieme\Method\OD-3, Hept\_IPA, 98\_2, 22°C, 1ml.met

Vial: 195 Injection Volume (µl): 1  
Run Time: 11.08.2014 13:24:55 Analysis Time: 08.04.2015 10:07:16




Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,253	6,523	201
2	2,593	0,737	204
3	2,947	80,658	205
4	3,340	12,082	204

## DAD-242 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,213	0,409	201
2	2,593	0,254	204
3	2,947	86,634	205
4	3,347	12,697	204
5	3,667	0,005	202



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

TiBu-155 rac {Data Description}

E:\EZDatenOC\Thieme\Method\OD-3, Hept\_IPA, 98\_2, 22°C, 1ml.met

Vial: 193 Injection Volume (μl): 1  
Run Time: 11.08.2014 13:58:04 Analysis Time: 08.04.2015 10:06:29

Spectrum Max Plot Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,007	0,410	204
2	2,247	3,954	201
3	2,947	47,801	204
4	3,347	47,835	204

DAD-242 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,227	0,112	201
2	2,780	0,076	242

3	2,947	49,816
4	3,347	49,996


204	204
204	204



**Chromatogram :L-C2; Hep\_IPA 200\_1; 0,5ml;  
240nm**

Method : L-C2; Hep\_IPA 200\_1; 0,5ml; 240nm  
User : AMH  
26.11.2014 22:27:16  
AMH  
tibu-191chir


Acquired : 26.11.2014 22:27:16  
Processed : 26.11.2014 22:37:23  
Printed : 26.11.2014 22:37:45  
ORGPC119  
Project1  
System 1 (Normal Phase)



**Chromatogram :L-C2; Hep\_IPA 200\_1; 0,5ml;  
240nm**

Method : L-C2; Hep\_IPA 200\_1; 0,5ml; 240nm  
User : AMH  
26.11.2014 22:16:11  
AMH  
tibu-191-rac

Acquired : 26.11.2014 22:16:11  
Processed : 26.11.2014 22:34:24  
Printed : 26.11.2014 22:34:32  
ORGPC119  
Project1  
System 1 (Normal Phase)



**Peak results :**

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%] [%]
1	UNKNOWN	6.30	10.27	122.0	18.0	10.268
2	UNKNOWN	6.97	89.73	939.2	157.2	89.732
Total			100.00	1061.2	175.2	100.000


**Peak results :**

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%] [%]
1	UNKNOWN	6.32	49.82	442.3	67.1	49.817
2	UNKNOWN	6.97	50.18	405.8	67.6	50.183
Total			100.00	848.1	134.6	100.000

**Chromatogram :L-C1; Hep\_IPA 300\_1; 0,5ml;  
215nm**

Method : L-C1; Hep\_IPA 300\_1; 0,5ml; 215nm  
User : TiBu  
09.10.2014 18:48:18  
TiBu  
TiBu-179-chir1

Acquired : 09.10.2014 18:48:18  
Processed : 23.10.2014 13:37:00  
Printed : 23.10.2014 13:37:38  
ORGPC119  
Project1  
System 1 (Normal Phase)




**Peak results :**

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	8.79	96.86	1293.6	338.1	96.856
2	UNKNOWN	10.17	3.14	33.8	11.0	3.144
Total			100.00	1327.4	349.1	100.000

**Chromatogram :L-C1; Hep\_IPA 300\_1; 0,5ml;  
215nm**

Method : L-C1; Hep\_IPA 300\_1; 0,5ml; 215nm  
User : Administrator  
09.10.2014 17:04:32  
TiBu  
Wil01192-rac

Acquired : 09.10.2014 17:04:32  
Processed : 10.10.2014 10:02:35  
Printed : 10.10.2014 10:02:45  
ORGPC119  
Project1  
System 1 (Normal Phase)




**Peak results :**

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	3.44	0.41	0.8	0.3	0.412
2	UNKNOWN	5.38	0.25	0.3	0.2	0.251
4	UNKNOWN	9.17	49.00	143.5	30.2	49.003
5	UNKNOWN	10.48	50.12	124.8	30.9	50.124
3	UNKNOWN	17.72	0.21	0.3	0.1	0.210
Total			100.00	269.6	61.7	100.000

**Chromatogram :L-C1; Hep\_IPA 300\_1; 0,5ml;  
215nm**

Method : L-C1; Hep\_IPA 300\_1; 0,5ml; 215nm  
User : TiBu  
09.10.2014 19:19:30  
TiBu  
TiBu-184-chir1

Acquired : 09.10.2014 19:19:30  
Processed : 23.10.2014 13:32:43  
Printed : 23.10.2014 13:33:36  
ORGPC119  
Project1  
System 1 (Normal Phase)




**Peak results :**

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	9.67	98.01	643.6	176.9	98.012
2	UNKNOWN	11.59	1.99	12.4	3.6	1.988
Total			100.00	655.9	180.4	100.000

**Chromatogram :L-C1; Hep\_IPA 300\_1; 0,5ml;  
215nm**

Method : L-C1; Hep\_IPA 300\_1; 0,5ml; 215nm  
User : TiBu  
01.12.2014 16:58:18  
TiBu  
TiBu-219

Acquired : 01.12.2014 16:58:18  
Processed : 01.12.2014 19:24:32  
Printed : 01.12.2014 19:24:58  
ORGPC119  
Project1  
System 1 (Normal Phase)



**Peak results :**

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	8.12	50.84	1013.4	459.1	50.843
2	UNKNOWN	9.66	49.16	922.7	443.9	49.157
Total			100.00	1936.1	903.1	100.000

## D-7000 HPLC System Manager Report

Analyzed: 07.10.14 17:30

Reported: 08.04.15 11:08  
Processed: 07.10.14 17:58

Data Path: D:\HSM\Alexander\DATA\0455\

Processing Method: 2\*L-A2 Hep/Et 98/2 0,5ml 220nm

System(acquisition): Sys 2

Application: Alexander

Sample Name: TiBu-185 ee

Injection from this vial: 1 of 1

Sample Description: Racemat


Series:0455

Vial Number: 1

Vial Type: UNK

Volume: 1,0 ul

Chrom Type: HPLC Channel : 1



Acquisition Method: 2\*L-A2 Hep/Et 98/2 0,5ml 220nm

Column Type: Chiralcel OD-H

Developed by: Alexander

Pump A Type: L-7100

Solvent A: n-Heptan

Solvent B: i-RrOH

Solvent C: Hept/IPA 100/1

Solvent D: Ethanol

Method Description: L-A2+L-A2, Hept/EtOH 98/2 0,5ml/min, 220 nm

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Area	Area %	BC
1	10,63	9964	0,215	BB
2	12,43	1874	0,040	BB
3	14,37	4451400	96,165	MC
4	15,54	120947	2,613	MC
5	18,99	1861	0,040	BB
6	23,17	42862	0,926	BB
		4628908	100,000	

Peak rejection level: 0

Channel 1 Noise: Not Measured

Channel 1 Drift: Not Measured

Configuration parameters:

Interface Module: D-7000

Channel 1 Detector: L-7400

Column Oven: None

Pump A: L-7100

Number of Solvents pump A: 4

External Instrument Software: None

Gradient Mode: Low

Channel 2 Detector: None

Autosampler: Manual

Pump B: None

Number of Solvents pump B: 1

Column Name: Chiralcel OD-H

Method Information:

Method Name: 2\*L-A2 Hep/Et 98/2 0,5ml 220nm

Developed by: Alexander

Description:

L-A2+L-A2, Hept/EtOH 98/2 0,5ml/min, 220 nm

Method History

Date	User	Comment
14.06.13 11:21	test	Method originated from ADH Hep/EtOH 10/90 0,5ml 280nm
14.06.13 11:21	test	

Pump Setup:

Main Pump (A) Pressure Limit: 10 to 150 bar

Pump A (L-7100):

Solvent A: n-Heptan

Solvent C: Hept/IPA 100/1

Solvent B: i-RrOH

Solvent D: Ethanol

Pump A (L-7100):

Pump Solvent and Event Table

Time (min)	%n-Hep	%i-RrO	%Hept/	%Ethan	Flow (ml/min)	Event 1	Event 2	Event 3	Event 4
0,0	98,0	0,0	0,0	2,0	0,500				

Channel 1 Detector (L-7400):

Response Time: 2.0 sec

Offset: 0,000 AU

Auto Data Sampling Mode: YES

Doubling Time: 10,00 min

Absorbance Range: 1 AU

Stop Time: 60,00 min

Initial Sampling Period: 200 msec

Detector Table

Time(min)	WL(nm)	Baseline
0,0	220	Auto Zero

Sampling Period Table

Time(min)	Period(msec)
0,00	200
10,00	400
30,00	800
70,00	1600
150,00	3200

Method DP for channel 1

**Calculation Method:**

Calculation Method: AREA%

Peak identification Window: % Time

UNK peaks identification rule: Closest peak

Update RT in component Table: YES Do blank subtraction: NO

Do library search: NO

**Component Table**

RT (min)	Window (%)	Func1	Func2	Func3	E-Conc	Tolerance (%)
0,01	10,00					

**Integration Table**

Time (min)	Function	Value/Status
0,00	NOISE	10
0,00	SMOOTHING	OFF
0,00	SENSITIVITY	20
0,00	N-METHOD	0

Perform system suitability test : NO  
Perform module performance test : NO  
Perform data diagnosis : NO

**Chromatogram Display Format:** Autoscale: YES

Autoscale Time Range: 0,00 to 600,00 min

Use alternate scale: NO

Scale to Full Chrom Time Range: YES Peak rejection level: 0 uV \* sec

Baseline overlay: YES Peak start-end markers: YES

Marker-In Signals: NO Peak labels: Time, None

Show integration time table: NO Show sampling period time table: NO

Show gradient curves: NO

Report channel 1 labels in the chromatogram overlay graph.

Picture in picture: None

**Report Format:** Reported peaks: All Peaks

Use primary layout: YES

Print primary layout report: YES

Acquisition DDE: NO

Reprocess DDE: NO

Concentration 1 Unit: Other

Concentration 1 scale factor: 1,0000

Concentration 1 divide by sample amount: NO

Concentration 2 Unit: Other

Concentration 2 name: Concentration 2 name:

Concentration 2 scale factor: 1,0000

Concentration 2 use component multiplier: NO

Injection report column 1 header: PK-NUM

Injection report column 2 header: RT

Injection report column 3 header: AREA

Injection report column 4 header: AREA%

Injection report column 5 header: BC

## D-7000 HPLC System Manager Report

Analyzed: 07.10.14 16:55

Reported: 08.04.15 11:08

Processed: 07.10.14 17:29

Data Path: D:\HSM\Alexander\DATA\0454\

Processing Method: 2\*L-A2 Hep/Et 98/2 0,5ml 220nm

System(acquisition): Sys 2

Series:0454

Application: Alexander

Vial Number: 1

Sample Name: TiBu-181 rac


Vial Type: UNK

Injection from this vial: 1 of 1

Volume: 1,0 ul

Sample Description: Racemat

Chrom Type: HPLC Channel : 1



Acquisition Method: 2\*L-A2 Hep/Et 98/2 0,5ml 220nm

Column Type: Chiralcel OD-H Developed by: Alexander

Pump A Type: L-7100

Solvent A: n-Heptan

Solvent B: i-RrOH

Solvent C: Hept/IPA 100/1

Solvent D: Ethanol

Method Description: L-A2+L-A2, Hept/EtOH 98/2 0,5ml/min, 220 nm

Chrom Type: HPLC Channel : 1

Peak Quantitation: AREA

Calculation Method: AREA%


No.	RT	Area	Area %	BC
1	7,75	2033	0,061	BB
2	9,81	4873	0,147	BB
3	11,59	7568	0,228	BB
4	12,43	544682	16,431	BB
5	14,41	1198834	36,164	MC
6	15,59	1200553	36,216	MC
7	17,58	0	0,000	
8	19,00	226080	6,820	BB
9	21,95	6553	0,198	BB
10	23,21	123803	3,735	BB
				3314979 100,000

Peak rejection level: 0

Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

TiBu-186-ee {Data Description}


E:\EZDatenOC\Doktorand 1\Method\AD-3, Hept\_EtOH, 95\_5, 22°C, 1ml.met  
Vial: 196 Injection Volume (μl): 2  
Run Time: 17.10.2014 14:24:51 Analysis Time: 08.04.2015 10:38:34



1: 210 nm, 4 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	2,093	1,066	204
2	11,447	1,324	229
3	12,313	97,610	229

Spectrum Max Plot Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	2,107	1,217	204
2	3,867	0,664	202
3	11,447	1,001	229
4	12,313	97,118	229

DAD-229 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	11,447	1,351	229
2	12,313	98,649	229




Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

## TiBu-182 rac {Data Description}

E:\EZDatenOC\Doctorand 1\Method\AD-3, Hept\_EtOH, 95\_5, 22°C, 1ml.met


Vial: 194 Injection Volume (µl): 2  
Run Time: 17.10.2014 12:23:08 Analysis Time: 08.04.2015 10:38:02



1: 210 nm, 4 nm Results		Minutes		
Pk #	Retention Time	Area Percent		Lambda Max
1	11.220	49	,787	229
2	12.180	50	,213	229

Spectrum Max Plot Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	11,220	49,864	229
2	12,180	50,136	229


DAD-229 nm				
Results				
Pk #	Retention Time	Area Percent	Lambda Max	
1	11,220	49,819	229	
2	12,180	50,181	229	



Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie


TiBu-276 ee {Data Description}

E:\EZDatenOC\Doctorand 1\Method\AD-3, Hept\_IPA, 90\_10, 22°C, 1ml.met

Vial: 195 Injection Volume (μl): 2  
Run Time: 25.02.2015 12:30:11 Analysis Time: 08.04.2015 10:40:15

Spectrum Max Plot Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	2,040	0,791	205
2	8,573	7,556	205
3	9,700	91,653	206


DAD-241 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	1,947	0,073	204
2	8,573	7,208	205
3	9,700	92,719	206



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

TiBu-275- rac {Data Description}


E:\EZDatenOC\Doktorand 1\Method\AD-3, Hept\_IPA, 90\_10, 22°C, 1ml.met

Vial: 192      Injection Volume (µl): 2  
Run Time: 25.02.2015 10:57:23      Analysis Time: 08.04.2015 10:39:47

1: 210 nm, 4 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	8,573	50,048	205
2	9,707	49,952	205

Spectrum Max Plot Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	2,040	0,341	205
2	8,573	49,726	205
3	9,707	49,933	205


DAD-241 nm Results			
Pk #	Retention Time	Area Percent	Lambda Max
1	8,573	50,050	205
2	9,707	49,950	205



Albert-Ludwigs-Universität Freiburg  
Institut für Organische Chemie und Biochemie

TiBu-297 ee {Data Description}

E:\EZDatenOC\Bury\Method\AD-3, Hept\_IPA, 93\_7, 22°C, 1ml.met


Vial: 192 Injection Volume (μl): 2  
Run Time: 17.03.2015 11:03:27 Analysis Time: 08.04.2015 10:41:23

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,033	1,718	206
2	12,033	6,318	205
3	12,987	91,965	206

DAD-241 nm Results


Pk #	Retention Time	Area Percent	Lambda Max
1	2,007	0,176	205
2	12,033	6,272	205
3	12,987	93,552	206



Albert-Ludwigs-Universität Freiburg  
**Institut für Organische Chemie und Biochemie**

TiBu-296-rac {Data Description}

E:\EZDatenOC\Bury\Method\AD-3, Hept\_IPA, 93\_7, 22°C, 1ml.met

Vial: 191      Injection Volume (µl): 2  
Run Time: 17.03.2015 10:40:04      Analysis Time: 08.04.2015 10:41:01

Spectrum Max Plot Results

Pk #	Retention Time	Area Percent	Lambda Max
1	2,007	2,731	205
2	12,033	48,384	206
3	12,993	48,885	206

DAD-241 nm Results

Pk #	Retention Time	Area Percent	Lambda Max
1	12,033	49,812	206
2	13,000	50,188	206

